Lexicon Pharmaceuticals (LXRX) Sets New 12-Month Low at $5.29

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) shares hit a new 52-week low during trading on Friday . The company traded as low as $5.29 and last traded at $6.00, with a volume of 82300 shares trading hands. The stock had previously closed at $7.70.

A number of research analysts have commented on LXRX shares. BidaskClub lowered Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, October 4th. Citigroup reduced their price target on Lexicon Pharmaceuticals from $27.00 to $26.00 and set a “buy” rating on the stock in a research report on Friday, November 2nd. Cowen restated a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Friday, November 2nd. Gabelli restated a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Friday, November 2nd. Finally, Zacks Investment Research lowered Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, January 8th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $21.85.

The stock has a market capitalization of $815.63 million, a PE ratio of -4.69 and a beta of 1.00.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported ($0.26) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.33) by $0.07. The business had revenue of $6.90 million for the quarter, compared to the consensus estimate of $12.56 million. Lexicon Pharmaceuticals had a negative return on equity of 1,247.65% and a negative net margin of 168.23%. The firm’s revenue was down 74.3% compared to the same quarter last year. During the same quarter last year, the business posted ($0.29) EPS. On average, equities analysts forecast that Lexicon Pharmaceuticals, Inc. will post -1.29 earnings per share for the current fiscal year.

Institutional investors have recently modified their holdings of the stock. Dynamic Technology Lab Private Ltd acquired a new stake in Lexicon Pharmaceuticals during the 2nd quarter worth $205,000. MetLife Investment Advisors LLC raised its stake in shares of Lexicon Pharmaceuticals by 49.8% in the 3rd quarter. MetLife Investment Advisors LLC now owns 35,705 shares of the biopharmaceutical company’s stock valued at $381,000 after purchasing an additional 11,862 shares during the period. Tekla Capital Management LLC acquired a new stake in shares of Lexicon Pharmaceuticals in the 3rd quarter valued at about $747,000. GSA Capital Partners LLP raised its stake in shares of Lexicon Pharmaceuticals by 321.7% in the 3rd quarter. GSA Capital Partners LLP now owns 74,586 shares of the biopharmaceutical company’s stock valued at $796,000 after purchasing an additional 56,900 shares during the period. Finally, Bank of Montreal Can raised its stake in shares of Lexicon Pharmaceuticals by 8,364.1% in the 3rd quarter. Bank of Montreal Can now owns 122,053 shares of the biopharmaceutical company’s stock valued at $1,302,000 after purchasing an additional 120,611 shares during the period.

WARNING: “Lexicon Pharmaceuticals (LXRX) Sets New 12-Month Low at $5.29” was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://www.com-unik.info/2019/01/18/lexicon-pharmaceuticals-lxrx-sets-new-12-month-low-at-5-29.html.

About Lexicon Pharmaceuticals (NASDAQ:LXRX)

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Further Reading: New Google Finance Tool and Screening Stocks

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit